Advanced Analysis Free Trading Signals Real Time Alerts

IQ-AI Shares Surge On US Patent Award

Practice Stock Trading Your capital is at risk
Updated: 11 Jun 2021

Shares of IQ-AI (LON: IQAI)are rallying on Friday after the company and its subsidiary, Imaging Biometrics, announced that its synthetic T1+C (Gad-Free) software application was awarded a patent by the US Patent and Trademark Office.

IQ-AI said the patent “underscores the potential of artificial intelligence (AI), its ability to streamline workflows, enhance diagnostic quality, and improve patient safety.”

The T1+C software application eliminates the need to intravenously inject contrast agent during medical imaging procedures. The fully automated AI platform accepts commonly acquired non-contrast medical images as inputs and outputs a synthetic contrast-enhanced image series that mimic actual, with contrast, images.

new-recommended-broker-banner

“This patented technology now available in the IQAI portfolio has the potential to directly impact routine clinical workflows globally,” said Trevor Brown, CEO of IQAI.

IQ-AI's share price is currently trading at 9.74p, up 23.68% after climbing to highs of 11.10p earlier in the session. In the past month, IQ-AI shares have gained 44.5%.

Should You Invest in IQ-AI Shares?

One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It's a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now

CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 68 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .